Navigation Links
Codexis Appoints Interim Chief Executive Officer
Date:2/17/2012

REDWOOD CITY, Calif., Feb. 17, 2012 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that effective immediately, the Board of Directors has appointed Peter Strumph as the company's interim Chief Executive Officer.  Alan Shaw, Ph.D. has resigned as President and Chief Executive Officer and from the Board of Directors to pursue other interests.  He will continue to serve as a special advisor to the Board of Directors.  The Board of Directors has appointed a special committee that will oversee the CEO search and transition.  Heidrick & Struggles has been retained for a worldwide search, which will include both internal and external candidates.

"We are grateful to Alan for his many years of service in leading Codexis from its inception and are pleased that he has agreed to serve as a special advisor to the Board," said Thomas Baruch, Chairman of the Board for Codexis, Inc.  "We are confident that Peter's executive leadership experience and deep understanding of the business will ensure a smooth transition during our search for a permanent CEO."

"Codexis has a tremendous leadership team in place, and I am pleased to continue supporting the company as it works to commercialize industrial enzymes in the biofuel, chemical and pharmaceutical industries," said Dr. Shaw.

Mr. Strumph was the Senior Vice President and Business Head of Pharmaceuticals, where he oversaw a 49% annual increase in pharmaceutical product sales in 2011, as well as the Senior Vice President of Commercial Operations since joining Codexis in 2010.  Mr. Strumph has more than twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry, including executive leadership positions for ten years at CV Therapeutics where he managed their operational, development and commercial activities.  He is a former Naval officer, and holds an MBA from the University of Pennsylvania's Wharton School of Business.   

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals and pharmaceutical intermediates.  Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol.  Partners and customers include global leaders such as Shell, Merck and Pfizer.  For more information, see www.codexis.com.

 

Contacts:
Investors: Jay Sarwar, ir@codexis.com, 650-421-8126
Media: Wes Bolsen, media@codexis.com, 650-421-8100


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Announces CFO Departure
2. Codexis to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on February 7, 2012
3. Codexis Reports Third Quarter 2011 Results
4. 50 Pharma Companies Worldwide Now Use Codexis In Process Development
5. Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil
6. Codexis, Raizen to Develop First Generation Ethanol
7. Codexis to Present at Three Investor Conferences in September
8. Codexis Presents Carbon Capture Update at DoE/NETL Conference
9. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
10. Codexis Reports Second Quarter 2011 Results
11. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):